APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease
Top Cited Papers
- 5 December 2013
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 369 (23), 2183-2196
- https://doi.org/10.1056/nejmoa1310345
Abstract
Among patients in the United States with chronic kidney disease, black patients are at increased risk for end-stage renal disease, as compared with white patients. In two studies, we examined the effects of variants in the gene encoding apolipoprotein L1 (APOL1) on the progression of chronic kidney disease. In the African American Study of Kidney Disease and Hypertension (AASK), we evaluated 693 black patients with chronic kidney disease attributed to hypertension. In the Chronic Renal Insufficiency Cohort (CRIC) study, we evaluated 2955 white patients and black patients with chronic kidney disease (46% of whom had diabetes) according to whether they had 2 copies of high-risk APOL1 variants (APOL1 high-risk group) or 0 or 1 copy (APOL1 low-risk group). In the AASK study, the primary outcome was a composite of end-stage renal disease or a doubling of the serum creatinine level. In the CRIC study, the primary outcomes were the slope in the estimated glomerular filtration rate (eGFR) and the composite of end-stage renal disease or a reduction of 50% in the eGFR from baseline. In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; PAPOL1 status and trial interventions or the presence of baseline proteinuria. In the CRIC study, black patients in the APOL1 high-risk group had a more rapid decline in the eGFR and a higher risk of the composite renal outcome than did white patients, among those with diabetes and those without diabetes (PAPOL1 were associated with the higher rates of end-stage renal disease and progression of chronic kidney disease that were observed in black patients as compared with white patients, regardless of diabetes status. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.)Keywords
This publication has 42 references indexed in Scilit:
- An integrated map of genetic variation from 1,092 human genomesNature, 2012
- Longitudinal Progression Trajectory of GFR Among Patients With CKDAmerican Journal of Kidney Diseases, 2012
- CKD in Hispanics: Baseline Characteristics From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC StudiesAmerican Journal of Kidney Diseases, 2011
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseThe New England Journal of Medicine, 2010
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010
- African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic AmericansHuman Molecular Genetics, 2010
- White/Black Racial Differences in Risk of End-stage Renal Disease and DeathThe American Journal of Medicine, 2009
- Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRDNephrology Dialysis Transplantation, 2009
- MYH9 is associated with nondiabetic end-stage renal disease in African AmericansNature Genetics, 2008
- MYH9 is a major-effect risk gene for focal segmental glomerulosclerosisNature Genetics, 2008